A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme

British Journal of Cancer

Volumn 95, Issue 2, 2006, Pages 197-203

  Guzman M ^a   Duarte, M J ^b   Blazquez C ^a   Ravina, J ^b   Rosa, M C ^b   Galve Roperh, I ^a   Sanchez C ^a   Velasco, G ^a   Gonzalez Feria L ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

Antitumoral drug; Cannabinoid; Glioblastoma multiforme; Pilot clinical study

Indexed keywords

CANNABINOID; CORTICOSTEROID; DRONABINOL; KI 67 ANTIGEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BRAIN EDEMA; BULIMIA; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG SAFETY; EUPHORIA; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHERMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT FAILURE; TUMOR CELL;

ADULT; AGED; BIOPSY; BRAIN NEOPLASMS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; RECEPTORS, CANNABINOID; SAFETY; SURVIVAL RATE; TETRAHYDROCANNABINOL; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 33745929641     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603236     Document Type: Article

References (27)

1. Afra D, Baron B, Bonadonna G, Burderr S, Parmar MKB, Stenning SP, Stewart LA, Curran Jr WJ, Green SB, Hildebrand J, Scott CB, Shapiro W, Souhami RL, Thomas D, Trojanowski T, Urtasun RC, Walker MD (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018
2. Blázquez C, Casanova ML, Planas A, del Pulgar TG, Villanueva C, Fernández-Aceñero MJ, Aragonés J, Huffman JW, Jorcano JL, Guzmán M (2003) Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17: 529-531
3. Blázquez C, González-Feria L, Ivarez L, Haro A, Casanova ML, Guzmán M (2004) Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64: 5617-5623
4. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345: 1008-1012
5. Dinnes J, Cave C, Huang S, Milne R (2002) A rapid and systematic review on the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br J Cancer 86: 501-505
6. Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M, Guzmán M (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6: 313-319
7. Gaoni Y, Mechoulam R (1964) Isolation, structure, elucidation and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646-1647
8. Gómez del Pulgar T, de Ceballos ML, Guzmán M, Velasco G (2002) Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 277: 36527-36533
9. Guzmán M (2003) Cannabinoids: potential anticancer agents. Nat Rev Cancer 3: 745-755
10. Hall W, Christie M, Currow D (2005) Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 6: 35-42
11. Hart S, Fischer OM, Ullrich A (2004) Cannabinoids induce cancer cell proliferation via tumor necrosis factor α-converting enzyme (TACE/ ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 63: 1943-1950
12. Hewlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202
13. Iversen L (2005) Long-term effects of exposure to cannabis. Curr Opin Pharmacol 5: 69-72
14. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225
15. Lonardi S, Tosoni A, Brandes AA (2005) Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev 31: 79-89
16. McKallip RJ, Nagarkatti M, Nagarkatti PS (2005) Delta-9- tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 174: 3281-3289
17. Mechoulam R, Hanus L (2000) A historical overview of chemical research on cannabinoids. Chem Phys Lipids 108: 1-13
18. Mechoulam R, Spatz M, Shohami E (2002) Endocannabinoids and neuroprotection. Sci STKE 129: RE5
19. Molina-Holgado E, Vela JM, Arevalo-Martín A, Almazán G, Molina-Holgado F, Borrell J, Guaza C (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol 3-kinase/Akt signaling. J Neurosci 22: 9742-9753
20. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA (1975) Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55: 597-602
21. Nagasubramanian R, Dolan ME (2003) Temozolomide: realizing the promise and potential. Curr Opin Oncol 15: 412-418
22. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884
23. Reardon DA, Rich JN, Friedman HS, Bigner DD (2006) Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24: 1253-1265
24. 2 cannabinoid receptor. Cancer Res 61: 5784-5789
25. Stupp R, van den Bent MJ, Hegi ME (2005) Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 5: 198-206
26. Yamanaka R (2006) Novel immunotherapeutic approaches to glioma. Curr Opin Mol Ther 8: 46-51
27. Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, Dubinett SM (2000) 9-Tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165: 373-380